Related Experiment Video
Updated: Aug 8, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Bromocriptine: long-term low-dose therapy in Parkinson's disease
Clinical Neuropharmacology
|January 1, 1986
Summary
Low-dose bromocriptine therapy offers significant benefits for Parkinson
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease is a progressive neurodegenerative disorder.
- Current treatments aim to manage motor symptoms like bradykinesia, tremor, and rigidity.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose bromocriptine in Parkinson's disease patients.
- To assess bromocriptine's role as a first-choice drug and in combination with levodopa.
Main Methods:
- A cohort of 39 Parkinson's disease patients received low-dose bromocriptine therapy (average 14.5 mg/day).
- Patient responses, including motor symptom improvement and adverse effects, were monitored over 2 years.
- Levodopa dosage adjustments and the impact of bromocriptine on treatment complications were analyzed.
Main Results:
- Significant improvement was observed in 25 of 39 patients.
- Bradykinesia improved in de novo patients; tremor and rigidity showed most improvement in levodopa-treated patients.
- Eighty percent of patients tolerating bromocriptine maintained response over 2 years. Bromocriptine did not induce dyskinesia or related phenomena in de novo patients.
Conclusions:
- Low-dose bromocriptine is effective and well-tolerated for managing Parkinson's disease symptoms.
- Combination therapy with bromocriptine and levodopa yielded the best results.
- Bromocriptine can be a valuable first-choice medication, especially for de novo Parkinson's disease patients.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...